Clinical Trial Update: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors [Phase 2]

View source ↗

Summary

Phase 2 study evaluating everolimus with bevacizumab for refractory malignant peripheral nerve sheath tumors has completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peripheral Nerve Sheath Tumors

Drugs mentioned

• Bevacizumab (bevacizumab)
• Everolimus (everolimus)

Snippet

Sponsor: Sarcoma Alliance for Research through Collaboration | Conditions: Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 2 | Status: COMPLETED | Results posted: 2019-03-06